

ANNUAL REVIEW OF CHRONOPHARMACOLOGY

Volume 5

BIOLOGICAL RHYTHMS AND MEDICATIONS

*Proceedings of the Third Conference of
Chronopharmacology, Nice, 14–17 March 1988*

Editors:

A. REINBERG

Fondation A. de Rothschild, Paris, France

M. SMOLENSKY

University of Texas, Houston, U.S.A.

G. LABRECQUE

Université de Laval, Québec, Canada



PERGAMON PRESS

OXFORD · NEW YORK · BEIJING · FRANKFURT
SÃO PAULO · SYDNEY · TOKYO · TORONTO

CONTENTS

Section 1 — Laboratory and Clinical Immunology and Inflammation

Co-chairmen: J.-P. BUREAU (Nimes, France)
E. HAEN (Munich, W. Germany)
F. LÉVI (Paris, France)

Circannual modulation of the circadian rhythm of polymorphonuclear cells J.-P. BUREAU, G. LABRECQUE, and M. COUPÉ	1
Increased evening exposure to cyclosporine and metabolites D. M. CANAFAX, R. J. CIPOLLE, W. J. M. HRUSHESKY, J. T. RABATIN, D. I. MIN, N. M. GRAVES, D. E. R. SUTHERLAND and L. D. BOWERS	5
Evaluation of various factors influencing the action of mouse α , β interferon on the chemiluminescence of mouse peritoneal macrophages V. CARRIÈRE, P. DORFMAN and M. BASTIDE	9
Two-dose chronopharmacokinetic optimization of cyclosporine in pancreas transplant patients R. J. CIPOLLE, D. M. CANAFAX, J. T. RABATIN, L. D. BOWERS, D. E. R. SUTHERLAND and W. J. M. HRUSHESKY	13
Chronobiological aspects of spondylarthritis C. FOCAN, M. ALVIN, V. MAZY, D. FOCAN-HENRARD, F. LÉVI and P. FRANCHIMONT	17
Alteration of circadian time structure of plasma proteins in patients with inflammation C. FOCAN, B. BRUGUEROLLE, C. ARNAUD, F. LÉVI, V. MAZY, D. FOCAN-HENRARD and G. BOUVENOT	21

Circadian-stage-specified effects of melatonin on human natural killer (NK) cell activity: <i>In vitro</i> and <i>in vivo</i> studies	25
G. GATTI, R. CARIGNOLA, R. MASERA, M. LUISA SARTORI, A. SALVADORI, E. MAGRO and A. ANGELI	
Circadian-shaped intrarenal cyclosporine delivery	29
S. A. GRUBER, R. J. CIPOLLE, D. M. CANAFAX, J. T. RABATIN, G. R. ERDMANN, P. E. HYNES, J. A. RITZ, F. H. GOULD and W. J. M. HRUSHESKY	
Influence of circadian changes in triglyceride concentrations on the pharmacokinetics and experimental toxicity of cyclosporine	31
D. R. LUKE, K. VADIEI and L. J. BRUNNER	
Circadian dosing-stage dependence in metabolic effects of ciclosporine in the rat	35
M.-F. MALMARY, K. KABBAJ and J. OUSTRIN	
Pain time profile under treatment with Ibuprofen in patients suffering from osteoarthritis (multicenter study)	39
J. MOERCHEL	
Chronopharmacologic optimization of oral ciclosporin A (CIA) in mice: A search for a compromise between least renal toxicity and highest immunosuppressive effects	43
A. PATI, I. FLORENTIN, G. LEMAIGRE, M. MECHKOURI and F. LÉVI	
Circadian variations of the efficiency of hepatitis B vaccination	45
L. PÖLLMANN and B. PÖLLMANN	
Seasonal variations of host resistance and <i>in vitro</i> antibody formation of spleen cells from the B6C3F1 mouse	49
H. RATAJCZAK, P. THOMAS, T. VOLLMUTH, D. HECK, R. SOTHERN and W. HRUSHESKY	
Section 2A — Neurobiology and Endocrinology	
Co-chairmen:	
	G. DAR COURT (Nice, France)
	R. REITER (San Antonio, Texas)
	W. RIETVELD (Leiden, Netherlands)
	Y. TOUITOU (Paris, France)
Further evaluation of the treatment of jet-lag by melatonin: A double-blind crossover study	53
J. ARENDT and M. ALDHOUS	

The phase relation of corticosterone and prolactin injections as a factor in the inhibition of hibernation in the thirteen-lined ground squirrel, <i>Citellus tridecemlineatus</i> J. T. BURNS and A. H. MEIER	57
Circadian and circannual variations of plasma calcitonin level in the rat: Influence of sex F. DUCHÂTEL, M.-F. MALMARY and J. OUSTRIN	61
The circadian pattern of plasma melatonin in anorexia nervosa: Its possible relationships with the pituitary-gonadal impairment E. FERRARI, P. A. BOSSOLO, S. FOPPA, S. COMIS, P. MAGNI, F. FRASCHINI and F. BRAMBILLA	65
The circadian rhythm of proopiomelanocortin-related peptides in aging E. FERRARI, P. A. BOSSOLO, S. FOPPA, M. FIORAVANTI, M. DALZANO, A. COSTA BARBÉ and F. FACCHINETTI	69
Regulation of the type II thyroxine-5'-deiodinase circadian rhythm in the rat frontal cerebral cortex J. M. GUERRERO, C. SANTANA, M. PUIG-DOMINGO, A. GONZALEZ-BRITO and R. J. REITER	73
Circadian rhythm parameters of clinical and endocrine functions in elderly subjects under treatment with various commonly used drugs E. HAUS, G. Y. NICOLAU, D. J. LAKATUA, C. BOGDAN, M. POPESCU, L. SACKETT-LUNDEEN, A. FRABONI and E. PETRESCU	77
Circadian and ultradian characteristics of plasma growth hormone in children of short stature R. C. HERMIDA, L. GARCÍA, C. LODEIRO and T. IGLESIAS	81
Biorhythmicity and EEG paroxysmal abnormalities in various forms of epileptic seizures M. F. MONGE-STRAUSS and F. MIKOL	85
The role of the lateral geniculate nuclei in phasic response to photic and pharmacologic stimuli L. P. MORIN, R. F. JOHNSON, L. SMALE, K. MICHELS and R. Y. MOORE	89
Testosterone replacement with a circadian pattern V. A. PLACE	93
Circadian rhythm of type II thyroxine-5'-deiodinase activity in the pineal gland: Controlling factors R. J. REITER, J. M. GUERRERO, C. SANTANA and M. PUIG-DOMINGO	95

The role of the hypothalamic suprachiasmatic nucleus in methamphetamine induced rhythms in behavior W. J. RIETVELD, J. RUIS and P. BUIJS	99
Simultaneous study of LH, cortisol, TSH and melatonin in normal subjects P. SCHULZ, J. RENARD, J. WIDMER, R. RIVEST, P. DICK and R. TISSOT	103
Stimulating effect of 5-methoxypsoralen on the secretion of melatonin E. SOUETRE, L. TAMARKIN, E. SALVATI, G. PACIOTTI, B. KREBS and G. DARCOURT	107
The circadian body temperature rhythm in estrous rats: Effects of environmental and endocrine manipulations F. SPENCER, H. B. JOHNSON, J. GANES and B. P. HSI	111
Time-dependent effects ACTH 1-17 on plasma GH and GH-RH in man Y. TOUITOU, A. REINBERG, P. GARNIER, A. BICAKOVA-ROCHER, Y. MOTOHASHI, A. BOGDAN and A. AUZÉBY	113
Section 2B — Neurobiology and Psychiatry	
Co-chairmen: G. DARCOURT (Nice, France) P. REDFERN (Bath, England) R. REITER (San Antonio, Texas) W. RIETVELD (Leiden, Netherlands) Y. TOUITOU (Paris, France)	
Changes from circadian to ultradian periodicities of the axillary temperature in three depressive patients A. BICAKOVA-ROCHER, A. REINBERG, A. GORCEIX, Y. MOTOHASHI and J. NOUGUIER	115
Chronopharmacologic evaluation of an "antifatigue" preparation. A double-blind, placebo control and cross-over study A. BICAKOVA-ROCHER, A. REINBERG, F. LÉVI, A. GORCEIX, Y. TOUITOU and G. METZGER	119
Chronic clorgyline alters the wheel-running response of Syrian hamsters to continuous bright light W. C. DUNCAN, P. G. SOKOLOVE and T. A. WEHR	123
Chronopharmacokinetics of imipramine and its metabolite desipramine in brain and plasma after single and chronic application of imipramine in rats L. HOLLE, Z. GÓRKA, B. LANGNER and B. LEMMER	127

Destruction of suprachiasmatic nuclei serotonergic fibers alters response of hamster activity rhythms to a monoamine oxidase inhibitor J. S. KRUSE	131
Time-dependent variations in morphine-induced analgesia G. LABRECQUE, D. LEPAGE-SAVARY and E. POULIN	135
Chronic antidepressants (imipramine, citalopram, mianserin) differently affect beta-receptor-effector-system in rat forebrain at different times of day B. LEMMER and H. GOTTHEINER	139
Effects of the antidepressant drugs clomipramine, fluoxetine and mianserin on free-running activity rhythms in the rat P. J. MITCHELL, P. H. REDFERN and J. STOLZ	143
Section 3 — Theophylline, Bronchodilators and Chest	
Co-chairmen: G. D'ALONZO (Houston, Texas) E. HAUS (St. Paul, Minnesota) G. KUNKEL (W. Berlin) J. JONKMAN (Groningen, Netherlands)	
Increased nocturnal bronchial hyperreactivity without increased airflow obstruction W. M. C. VAN AALDEREN, D. S. POSTMA, G. H. KOËTER, J. GERRITSEN and K. KNOL	147
A study of the circadian rhythm of serum theophylline levels (STLs) in asthmatic children treated with three sustained-release theophylline (SRT) formulations A. BACULARD, P. AYMARD and G. TOURNIER	151
A preliminary study of the circadian rhythm of serum theophylline levels (STLs) in asthmatic infants treated with sustained-release theophylline (SRT) formulation A. BACULARD, J. COUVREUR, B. DUBOIS, P. AYMARD and G. TOURNIER	153
The utility of the estimated T_w/T_{tot} in evaluating a long acting sympathomimetic agent used for nocturnal asthma R. P. BAUGHMAN and R. G. LOUDON	157
Chronopharmacokinetics of theophylline from a once-a-day tablet dosed in the morning and at night C. J. BETLACH, A. B. STRAUGHN, E. J. JARVI, C. F. RYAN, J. C. KISICKI and M. A. GONZALEZ	161

Circadian chronesthesia of the airways of healthy adults to the β -agonist bronchodilator isoproterenol	163
A. BROWN, M. SMOLENSKY, G. D'ALONZO, H. FRANKOFF, L. GIANOTTI and J. NILSESTUEN	
Comparison of the kinetics and effects of sustained-release theophylline scheduled conventionally and once-daily mornings or evenings in adult asthmatics	167
H. FRANKOFF, M. SMOLENSKY, G. D'ALONZO and J. TOMLINSON	
Effect of unequal twice daily theophylline on the circadian variation in the expression of β_2 -adrenoceptor sites on peripheral mononuclear leucocytes (MNL)	171
E. HAEN, I. LANGENMAYER, H. EMSLANDER, H. HEUSINGER, M. HALLEK and J. REMIEN	
Circadian variation in the expression of β_2 -adrenoceptor sites in male asthmatic patients	175
E. HAEN, I. LANGENMAYER, H. EMSLANDER, N. WEBER and J. REMIEN	
Appearance of circannual variations of different immune parameters in the bronchoalveolar lavage (BAL) fluid in patients with chronic bronchitis after treatment with a bacterial lysate	179
M. HALLEK, B. EMMERICH, R. BUSCH, E. HAEN and H. P. EMSLANDER	
A pharmacokinetic model of sustained-release theophylline with circadian rhythmic input and correlated with pulmonary function response	183
A. S. KAPADIA and B. P. HSI	
Circadian variations of lymphocyte subpopulations without and with theophylline	187
G. KUNKEL, C. RAUFFUS, R. KUNZE, B. SIEBERT and D. ALBRIGHT	
Circadian variations of β_2 -adrenoceptors with and without theophylline	189
G. KUNKEL, B. SIEBERT, M. SUERMONDT, R. SPIERER and D. ALBRIGHT	
Circadian rhythm in forced expiratory flows in asthmatic children: Modification after bronchodilators (ipratropium and fenoterol)	191
R. LAMY, J. JUST, M. BOULÉ, A. BACULARD, A. SARDET, A. GRIMFELD, G. TOURNIER and F. GIRARD	

- Effect of a mucolytic agent on biologic rhythms of cough and sputum production 195
 R. G. LOUDON and R. P. BAUGHMAN
- Comparison of the relationship between two measures of bronchial patency, peak expiratory flow (PEF) and forced expiratory volume (FEV₁), over 24 hr under steady-state theophylline treatment 197
 A. A. MELTZER, M. H. SMOLENSKY, G. E. D'ALONZO, R. B. HARRIST and P. H. SCOTT
- Periodicities of patient admissions to an emergency department for asthma, chronic obstructive pulmonary disease and/or theophylline toxicity 201
 R. W. MORRIS, J. B. LEIKIN, M. K. PATEL and M. ZELL
- Chronopharmacokinetic simulation of a circadian rhythm in theophylline disposition during a constant-rate intravenous infusion of aminophylline in the dog 205
 R. J. RACKLEY, M. C. MEYER and A. B. STRAUGHN
- Oral morning dosing of corticosteroids in long term treated cortico-dependent asthmatics: Increased tolerance and preservation of the adrenocortical function 209
 A. REINBERG, Y. TOUITOU, M. BOTBOL, P. GERVAIS, D. CHAOUAT, F. LÉVI and A. BICAKOVA-ROCHER
- Influence of different evening intake times of sustained-release theophylline formulation Euphyllong^o (BY158) on pharmacokinetics and peak expiratory flow values after individual dose titration 213
 B. SIEBERT, G. KUNKEL, K. BORNER, H. W. STAUDINGER and V. W. STEINIJANS

Section 4 — General Chronopharmacology

- Co-chairmen: P. BÉLANGER (Québec, Canada)
 B. BRUGUEROLLE (Marseille, France)
 S. NAKANO (Ehime, Japan)
 R. STURTEVANT (Maywood, Illinois)
- Circadian periodicity in the glutathione concentration of rat liver 215
 P. M. BÉLANGER, M. DESGAGNÉ and B. BRUGUEROLLE
- Day-night variations in the activity and composition of the microsomal mixed function oxidase of rat liver 219
 P. M. BÉLANGER and M. LALANDE

Bupivacaine chronokinetics in man after a peridural constant rate infusion	223
B. BRUGUEROLLE, M. DUPONT, P. LEBRE and G. LEGRE	
Temporal variations of membrane permeability to local anaesthetic agents, bupivacaine and mepivacaine, documented by their erythrocytic passage	227
B. BRUGUEROLLE and M. PRAT	
Circadian rhythm in serum zinc concentrations in healthy humans	231
J. C. CAL, F. DUMAS, F. PELEN, J. M. RAYMOND, J. CAMBAR and M. AMOURETTI	
The mechanism of the chronohepatotoxicity of chloroform in rat: Correlation between binding to hepatic subcellular fractions and histologic changes	235
M. DESGAGNÉ, M. BOUTET and P. M. BÉLANGER	
Circadian variations in mice erythrocyte membrane permeability to sodium and potassium	239
C. DORIAN, P. CATROUX, B. BRUGUEROLLE and J. CAMBAR	
Insects as animal models for chronopharmacological research	243
D. K. HAYES and N. O. MORGAN	
Dosing-time and sex related differences in the pharmacokinetics of cefodizime as well as in cortisol circadian rhythm	247
J. H. G. JONKMAN, A. REINBERG, B. OOSTERHUIS, O. E. DE NOOD, F. A. KERKHOF, Y. MOTOHASHI, F. LÉVI and F. CARANDENTE	
Circadian variations of nicotine-induced stimulant effects on ambulatory activity and drinking produced by daily administration in rats	249
T. KITA, M. SHIRASE, H. KONDOH, T. NAKASHIMA and Y. KUROGOCHI	
Diurnal variations in the local anesthetic effect of carticaine plus epinephrine (ultracain D-S ^R) in patients with caries — studies with an electronic pulp tester	253
B. LEMMER and R. WIEMERS	
Is acetylator phenotype distribution dependent of circadian rhythms?	257
M. OLLAGNIER, J. P. GAY, Y. CHERRAH, H. DECOUSUS and A. REINBERG	

Retrospective analysis of non-equidistant pharmacological data	259
R. PIERRE, J. DE PRINS, E. MALHERBE, P. MANCHON and S. MORE	
Chronotoxicity and chronokinetics of two local anaesthetic agents, bupivacaine and mepivacaine, in mice	263
M. PRAT and B. BRUGUEROLLE	
Diurnal oscillations in salivary levels of quinine following a single dose administration to human volunteers	267
B. RAMESH RAO and D. RAMBHAU	
Circadian ethanol exposure related to fetal growth and development in mice	271
I. SAUERBIER	
Maturation of circadian behavior rhythms in the first year of human life	273
U. SCHMID, R. LANG, M. HALLEK, D. HEIMER-LANG, M. WERRES, R. SCHMID and T. HELLBRÜGGE	
A method for the repetitive collection of small blood samples from unanesthetized rats	277
K. SCHÜMANN, E. RICHTER and E. HAEN	
Analysis of variance in human chronopharmacology. An old method in a new area of research	281
K. STEPHAN, R. DOROW, K. WEGSCHEIDER and B. STREITBERG	

Section 5 — Ulcerogenesis, H₂-Antagonists, Diabetes and Nutrition

Co-chairmen:	A. MARKIEWICZ (Katowice, Poland)
	J. MOORE (Salt Lake City, Utah)
	S. SZABO (Boston, Massachusetts)
Ultrannual rhythm of stimulated gastric acid secretion in duodenal ulcer (DU)	283
J. P. ACCARY, M. MERROUCHE, D. RIGAUD, J. VATIER and M. MIGNON	
Nizatidine 300mg H.S. compared with cimetidine 800 mg H.S. in the treatment of acute duodenal ulcer	285
M. CLOUD and W. OFFEN	
The circadian effect of alloxan-diabetes on the timed regulation of hepatic pyruvate kinase from mice	287
R. J. FEUERS, R. A. MITTELSTAEDT, L. E. SCHEVING, T. H. TSAI and J. HUNTER	

The suppression of nocturnal acid secretion by H.S. famotidine therapy is sufficient to heal benign gastric ulcers T. J. HUMPHRIES and R. G. BERLIN	291
Circadian variations in insulin and alloxan sensitivity noted in blood glucose alterations in normal and diabetic mice J. D. HUNTER, J. P. MCGEE, J. SALDIVAR, T. TSAI, R. FEUERS and L. E. SCHEVING	295
Circadian variation of catecholamines excretion and skin basic resistance in children with insulin dependent diabetes D. KIEŁCZEWSKA-MROZIKIEWICZ, A. MROZIKIEWICZ and E. CHMARA	299
Diet and mealtiming as circadian synchronizers D. J. LAKATUA, M. HAUS, C. BERGE, L. SACKETT-LUNDEEN and E. HAUS	303
Seasonal variation in the incidence of bleeding ulcer A. MARBELLA, D. GRAHAM and M. SMOLENSKY	307
Chronosupplementation after gastrectomy A. MARKIEWICZ, H. BOLDYS, D. SKRZYPEK and J. KALACIŃSKI	311
Continuous infusion of famotidine maintains high gastric pH in duodenal ulcer (DU) H. MERKI, L. WITZEL, M. LANGMAN, D. KAUFMANN, J. NEUMANN, J. RÖHMEL and R. WALT	315
Manipulation of feeding schedule can modify the circadian rhythms of toxicity and kinetics of theophylline in mice S. NAKANO, S. OHDO and N. OGAWA	317
Timing of evening meal and ranitidine administration on patterns of 24hr intragastric pH W. C. ORR, M. ALLEN, A. FINN and M. G. ROBINSON	321
Circadian rhythms of gastrointestinal peptides in ovariectomized rats: Effects of estradiol and progesterone treatment J. N. PASLEY and P. L. RAYFORD	323
Effect of seasonal variations on serum neutral amino acids in response to stress in rat A. G. ROBERGE	327
Effect of seasonal variations on blood parameters in response to stress in cat A. G. ROBERGE and L. THIBAUT	331

Circadian variation in the pharmacodynamic effect of intravenous ranitidine	335
S. W. SANDERS, J. G. MOORE, K. N. BUCHI and A. L. BISHOP	
Circadian dissociation between drug-induced gastric mucosal lesions and gastric secretion in the rat	339
S. SZABO, C. ROGERS and K. J. VENER	
Relationship between activity–rhythm shift by daytime restricted feeding and ulcer-development in activity–stress procedure	341
K. WATANABE, C. HARA and N. OGAWA	
Section 6 — Cancer	
Co-chairmen:	
I. ASHKENAZI (Tel Aviv, Israel)	
C. FOCAN (Liège, Belgium)	
R. VON ROEMELING (Lubbock, Texas)	
L. SCHEVING (Little Rock, Arkansas)	
Twenty-four hour variation in self-administration of morphine sulfate (MS) and hydromorphone (H) by post-surgical gynecologic cancer patients	343
S. E. AUVIL-NOVAK, R. D. NOVAK, M. H. SMOLENSKY, J. J. KAVANAGH, J. W. KWAN and J. T. WHARTON	
The role of circadian mitotic control for the promotion of preneoplastic lesions initiated by diethylnitrosamine (DEN)	347
H. BARBASON, B. BOUZAHZAH and M.-C. MORMONT	
Toxicities and tissue pharmacokinetics of oxaliplatin and carboplatin depend upon their dosing time in mice	351
N. A. BOUGHATTAS, F. LÉVI, B. HECQUET, G. LEMAIGRE, A. ROULON, C. FOURNIER and A. REINBERG	
Circadian cellular proliferation in human rectal mucosa	355
K. N. BUCHI, N. H. RUBIN and J. G. MOORE	
Chronotoxicity of anti-cancer drugs: II. Recovery pattern	357
R. CARLEBACH, M. RAVID, L. PELEG, I. ASHKENAZI and Y. KITAY-COHEN	
Modulation of the circadian rhythm in methotrexate toxicity in the rat by melatonin and photoperiod	359
J. ENGLISH, G. W. AHERNE and J. ARENDT	
Observation of circadian variations of serum thymidine kinase levels in control and tumor patients	361
M. HALLEK, B. EMMERICH, A. REICHLÉ, H. D. SCHICK, R. SENEKOWITSCH and A. REINBERG	

Chronotoxicity of anti-cancer drugs: I. Immediate effects Y. KITAY-COHEN, I. ASHKENAZI, M. RAVID, L. PELEG and R. CARLEBACH	365
Circadian rhythm in murine tolerance for the anticancer agent mitomycin-C (MIT-C) F. KLEIN, L. DANOBER, A. ROULON, G. LEMAIGRE, M. MECHKOURI and F. LÉVI	367
Circadian gating of DNA synthesis and its relationship to surgical debulking in human ovarian cancer R. R. KLEVECZ and P. S. BRALY	371
Etoposide and cisplatin in advanced solid tumors: Results of a study of chronotolerance I. KRAKOWSKI, F. LÉVI, M. MECHKOURI, T. CONROY, E. LUPORSI, B. WEBER and R. METZ	373
Treatment of childhood acute lymphoblastic leukemia with 6-mercaptopurine: Circadian variability of efficacy, bioavailability and pharmacokinetics G. E. RIVARD, K.-T. LIN, C. INFANTE-RIVARD, J. M. LECLERC and F. VARIN	377
Differential effect of interleukin-2 on [³ H]TdR incorporation into DNA in the thymus, spleen and bone marrow of CD2F ₁ male mice L. A. SCHEVING, T. H. TSAI, R. J. FEUERS, M. H. SMOLENSKY, J. D. YOUNG and L. E. SCHEVING	381
A circadian study of cell cycle distribution in non-Hodgkin lymphomas R. SMAALAND, K. LOTE, O. D. LAERUM and Z. VOKAC	383
Circadian stage not time of day characterizes doxorubicin susceptibility rhythm of mice in continuous light R. B. SOTHERN, F. HALBERG and W. J. M. HRUSHESKY	385
Profound circadian stage dependence of mitomycin-C toxicity R. B. SOTHERN, R. HAUS, T. R. LANGEVIN, J. A. POPOVICH, M. WICK, R. v. ROEMELING and W. J. M. HRUSHESKY	389
Clinical chronopharmacokinetics of doxorubicin (DXR) A. SQALLI, J. OUSTRIN, G. HOUIN, R. BUGAT, P. CANAL and M. CARTON	393
Circadian influence of interleukin-2 in stimulating DNA synthesis in the lung, liver and pancreas of CD2F ₁ male mice T. H. TSAI, L. A. SCHEVING, R. J. FEUERS, J. D. YOUNG and L. E. SCHEVING	397

- Sources of variability of dihydropyrimidine dehydrogenase activity in human blood mononuclear cells 399
 M. TUCHMAN, R. v. ROEMELING, R. M. LANNING, R. B. SOTHERN and W. J. M. HRUSHESKY

Round Table — Drug Delivery Systems and Pumps for Timing Medications

Chairman: W. J. M. HRUSHESKY (Minneapolis, Minnesota)

- Chronotherapy of patients with metastatic colorectal cancer with 5-fluorouracil (5-FU) and oxaliplatin (1-OHP), automatically delivered via a programmable external pump. Preliminary results 403
 J. P. CAUSSANEL, F. LÉVI, J. L. MISSET, A. DESCORPS DECLERE, R. ADAM, H. BISMUTH, A. REINBERG and G. MATHÉ
- Time-modulating controlled delivery of peptide/protein drugs for possible applications in chronotherapy 407
 Y. W. CHIEN
- Circadian variations of vindesine serum concentrations during continuous infusion 411
 C. FOCAN, V. MAZY, J. ZHOU, R. RAHMANI and J. P. CANO
- Implantable therapeutic systems 415
 J. KOST
- Ambulatory 5-day chronotherapy of colorectal cancer with continuous venous infusion of 5-fluorouracil (5-FU) at circadian-modulated rate. Preliminary results 419
 F. LÉVI, R. ADAM, A. SOUSSAN, J. P. CAUSSANEL, M. BENAVIDES, J. L. MISSET, F. BURKI, A. REINBERG, M. SMOLENSKY, H. BISMUTH and G. MATHÉ
- Pump delivered insulin and home monitored blood glucose in a diabetic patient: Retrospective and chronophysiologic evaluation of 3-year time series 423
 A. REINBERG, P. DROUIN, M. KOLOPP, L. MÉJEAN, F. LÉVI, G. DEBRY, M. MECHKOURI, G. DI COSTANZO and A. BICAKOVA-ROCHER
- Circadian timing and mode of fluoropyrimidine administration markedly impact organ-specific toxicity and maximal dose intensity 427
 R. v. ROEMELING, J. RABATIN, M. TUCHMAN and W. J. M. HRUSHESKY

- Feasibility, safety and accuracy of an automated drug delivery system suitable for chronochemotherapy in pediatric patients 431
 J. M. A. VAN TORNOUT, M. E. NESBIT, Jr., B. BOSTROM,
 N. K. C. RAMSAY, S. SOMANI, T. LANGEVIN, R. LANNING,
 R. VON ROEMELING and W. J. M. HRUSHESKY

Section 7 — Cardiovascular and Renal Systems

- Co-chairmen: J. CAMBAR (Bordeaux, France)
 H. DECOUSUS (St. Etienne, France)
 B. LEMMER (Frankfurt, W. Germany)
- Circadian variations in post ischemic acute renal failure in rats 433
 P. CATROUX, C. DORIAN and J. CAMBAR
- Role of renin angiotensin system in amikacin chrononephrotoxicity 437
 C. DORIAN, P. CATROUX and J. CAMBAR
- Does the circadian variation of β_2 -adrenoceptor sites on peripheral mononuclear leucocytes (MNL) reflect the circadian variation of different MNL subsets? 441
 E. HAEN, T. LEDERER, P. RIEBER, P. SCHLEICHER,
 I. LANGENMAYER, M. HALLEK and J. REMIEN
- 24-hour variations in the distribution of labeled microspheres to the intestine, liver and kidneys 445
 G. LABRECQUE, P. M. BÉLANGER, F. DORÉ and
 M. LALANDE
- Nocturnal blood pressure in sleep apnea, effect of nasal continuous positive airway pressure (nCPAP) 449
 J. MAYER, H. BECKER, U. BRANDENBURG, T. PENZEL,
 J. H. PETER, R. STOOHS, M. WEINER and P. v. WICHERT
- Alteration of circadian rhythms of blood pressure by delayed bed-time sleep schedule 453
 Y. MOTOHASHI and T. TAKANO
- Circadian variation in digoxin pharmacokinetics 457
 A. MROZIKIEWICZ, A. JABŁECKA, Z. ŁOWICKI and
 E. CHMARA
- Seasonal variations in gentamicin nephrotoxicity in rats 461
 C. PARIAT, P. COURTOIS, J. CAMBAR, A. PIRIOU and
 S. BOUQUET
- Biological rhythms of blood coagulation and of the effect of warfarin in rats 465
 G. SOULBAN and G. LABRECQUE

Circadian variation of prohormone atrial natriuretic factors 1-30, 31-67 and 99-126 in man	469
D. L. VESELY, C. J. WINTERS, A. L. SALLMAN, D. M. RICO, J. MEADOWS, B. LeMAY, J. HARRIS, S. D. LUNNINGHAM and V. MELHORN	
Effects of different stimuli (isoprenaline, Gpp(NH)p, forskolin) on circadian rhythms in cAMP content and adenylate cyclase activity in the rat heart	473
K. WITTE and B. LEMMER	
Author Index	477
Subject Index	481

EFFECT OF UNEQUAL TWICE DAILY THEOPHYLLINE ON THE CIRCADIAN VARIATION IN THE EXPRESSION OF β_2 -ADRENOCEPTOR SITES ON PERIPHERAL MONONUCLEAR LEUCOCYTES (MNL)

E. Haen,^{*} I. Langenmayer,^{*} H. Emslander,^{**} H. Heusinger,^{***} M. Hallek^{**} and J. Remien^{*}

^{*}Walther-Straub-Institute of Pharmacology and Toxicology, Nussbaumstr. 26, D-8000 München 2, F.R.G.

^{**}I. Medical Clinic, Klinikum r.d. Isar, Ismaninger Str. 22, D-8000 München 80, F.R.G.

^{***}Central Hospital Gauting, D-8035 Gauting, F.R.G.

KEY WORDS

circadian variation, β_2 -adrenoceptors, peripheral mononuclear leucocytes (MNL), nocturnal asthma, theophylline

INTRODUCTION

The reaction of hormone receptors to systemically administered drugs may be studied on intact mononuclear leucocytes (MNL). β_2 -adrenoceptors respond to β -sympathomimetics with a so called "down-regulation", i.e. a decrease of the number of expressed receptor sites (Aarons et al 1983). The opposite effect, receptor "up-regulation" may be achieved with β -blockers such as propranolol (Aarons et al 1980). Theophylline may interact with the intracellular cAMP system which in MNL is coupled among others to β_2 -adrenoceptors. This drug is currently being recommended for the prevention of nocturnal asthmatic attacks (Barnes 1984). It is of interest, therefore, to study the effect of therapeutic theophylline concentrations on the circadian variation in the expression and function of β_2 -adrenoceptor sites (Pangerl et al 1986, Haen 1987) in male asthmatic patients suffering from nocturnal asthma (Haen et al 1988).

MATERIALS AND METHODS

Four so far untreated male asthmatic patients, 19-27 years of age, were given 1050 mg/day theophylline (Bronchoretard^R, Klinge Pharma Munich/FRG). The dosage was divided in 1/3 (350 mg) at 08h00 and 2/3 (700 mg) at 22h00 because of the circadian variation in the serum concentration/time profile of this drug (Scott et al 1981). Before treatment and on day 7 venous blood was drawn at 14h00, 18h00, 22h00, 02h00, 06h00, 10h00, and again at 14h00. The blood specimen were immediately assayed for the number of high affinity β -adrenergic binding sites (B-max) on intact lymphocytes, using a receptor binding assay (Anhäupl et al 1988) with ¹²⁵I-cyanopindolol, a β -antagonist. β_2 -adrenoceptor coupled adenylate cyclase was stimulated by incubating the intact cells with 10^{-7} mol/l isoprenaline for 5 minutes at 37°C; the increase of intracellular cAMP above basal values was determined by radio-immunoassay after cell disruption.

Directly after venopuncture respiratory function was assessed using a computer based, room-restricted spirometer. Among other variables the best of three peak expiratory flow (PEF) readings was recorded.

The subjects were asked to follow a regular life-style for the two weeks preceding the study with bed rest between 23h00 and 07h00. On the day of the study the subjects stayed in the clinical pharmacological research unit of the hospital. They continued to follow their normal daily routine. Subjects were asked to record meal times, the consumption of alcohol and coffee. All were non-smokers.

Circadian variations were statistically validated by the single cosinor method (Halberg *et al.* 1967) and by analysis of variance (anova). Significance limit was $p < 0.05$.

RESULTS

The theophylline dosing scheme resulted in plasma drug concentrations of 8-13 $\mu\text{g/ml}$ on day 7 (Fig. 1). Respiratory function markedly improved, which matched the subjective relief of complaints. Especially the "nocturnal dip" in peak expiratory flow was much less pronounced (Fig. 2) indicating that theophylline was most effective between 02h00 and 06h00 when plasma drug concentrations were in the upper range (Fig. 1).




Fig. 1. Theophylline plasma concentration in male asthmatic patients on day 7 of 1050 mg/d theophylline ($\bar{x} \pm \text{SE}$).




Fig. 2. Peak expiratory flow of male asthmatic patients before and on day 7 of 1050 mg/d theophylline ($\bar{x} \pm \text{SE}$).

The circadian variation in the expression of β_2 -adrenoceptor sites was preserved after treatment with theophylline (Fig. 3). Peak daytime values, however, were reduced resulting in a smaller circadian range of 63.1-139.0 % of 24h-mean (compared to 59.1-155.2 % of 24h-mean before treatment). The 24h-mean itself was lowered from 1014 ± 119 sites/cell to 853 ± 87 sites/cell ($\bar{x} \pm SE$) equivalent to a receptor down-regulation of 15.9 % (not significant).




Fig. 3. β_2 -Adrenoceptor density on peripheral mononuclear leucocytes of male asthmatic patients before and on day 7 of 1050 mg/d theophylline ($\bar{x} \pm SE$).

In spite of the reduced β_2 -adrenoceptor density during the day basal cAMP contents of the cells were equally elevated throughout the 24 hours (Fig. 4). The circadian variation was preserved with a 24h-mean increased from 4.8 ± 0.4 pmol/ 10^6 cells to 8.3 ± 0.6 pmol/ 10^6 cells ($\bar{x} \pm SE$, not significant). β_2 -adrenoceptor coupled adenylate cyclase could still be stimulated by 10^{-7} mol/l isoprenaline to 9.6 ± 0.6 pmol/ 10^6 (24h-mean $\pm SE$) cells (increase of 1.3 pmol/ 10^6 cells compared to 2.0 pmol/ 10^6 cells before treatment, Fig. 4, Haen et al 1988).




Fig. 4. Cyclic AMP content of peripheral mononuclear leucocytes from male asthmatic patients on day 7 of 1050 mg/d theophylline before and after in vitro stimulation by 10^{-7} mol/l isoprenaline ($\bar{x} \pm SE$).

DISCUSSION

A 25 % down-regulation of β_2 -adrenoceptors by theophylline treatment was already described by Scarpace et al in 1982 in a non-chronobiological study. Such an effect could be mediated via stimulation of catecholamine secretion by theophylline (Hedquist et al 1978) and/or via an increased intracellular cAMP content, since a cAMP dependent protein kinase has been suggested to be responsible for receptor down-regulation (Helmreich & Pfeuffer 1985). The adrenoceptor down-regulation by theophylline is clinically irrelevant in asthma therapy, since respiratory function is on the contrary markedly improved. However, the reduced response of the adenylate cyclase system to β -adrenergic stimuli (as compared to pretreatment, Haen et al 1988) may be relevant to a combination of theophylline with β -sympathomimetic drugs. β -Sympathomimetics may increase the effectiveness of a theophylline therapy, but both drugs are less than additive in effect.

REFERENCES

1. Aarons RD, Nies AS, Gal J, Hegstrand LR, Molinoff PB (1980). Elevation of β -Adrenergic Receptor Density in Human Lymphocytes after Propranolol Administration. J Clin Invest 65, 949-957
2. Aarons RD, Nies AS, Gerber JG, Molinoff PB (1983). Decreased Beta Adrenergic Receptor Density on Human Lymphocytes after Chronic Treatment with Agonists. J Pharmacol Exp Ther 224, 1-6
3. Anhäupl T, Liebl B, Remien J (1988). Kinetic and Equilibrium Studies of (-)¹²⁵Iodocyanopindolol Binding to β -Adrenoceptors in Human Lymphocytes: Evidence for the Existence of Two Classes of Binding Sites. J Rec Res 8, (in press)
4. Barnes PJ (1984). Nocturnal Asthma: Mechanisms and Treatment. Brit Med J 288, 1397-1398
5. Haen E (1987). The Peripheral Lymphocyte as Clinical Model for Receptor Disturbances: Asthmatic Diseases. Bull Eur Physiopathol Resp 22, 539-541
6. Haen E, Langenmayer I, Emslander H, Weber N, Remien J (1988). Circadian Variation in the Expression of β_2 -Adrenoceptor Sites in Male Asthmatic Patients. Ann Rev Chronopharmacol 5 (this volume)
7. Halberg F, Tong YL, Johnson EA (1967). Circadian System Phase - An Aspect of Temporal Morphology; Procedures and Illustrative Examples. in: The Cellular Aspects of Bio-rhythms (ed H v Mayersbach), Springer Verlag Berlin/Heidelberg/New York, pp 20-48
8. Hedquist P, Fredholm BB, Ölundh S (1978). Antagonistic Effects of Theophylline and Adenosine on Adrenergic Neuroeffector Transmission in the Rabbit Kidney. Circul Res 43, 592-598
9. Helmreich EJM, Pfeuffer T (1985). Regulation of Signal Transduction by β -Adrenergic Hormone Receptors. Trends Pharmacol Sci 6, 438-443
10. Pangerl A, Remien J, Haen E (1986). The Number of β -Adrenoceptor Sites on Intact Human Lymphocytes Depends on Time of Day, on Season, and on Sex. Ann Rev Chronopharmacol 3, 331-334
11. Scarpace PJ, Littner MR, Tashkin DP, Abrass IB (1982). Lymphocyte Beta-Adrenergic Refractoriness Induced by Theophylline or Metaproterenol in Healthy and Asthmatic Subjects. Life Sci 31, 1567-1573
12. Scott PH, MacLeod S, Newth C (1981). Sustained Release Theophylline for Childhood Asthma. Evidence for Circadian Variation of Theophylline Pharmacokinetics. J Pediatrics 99, 476-479

ACKNOWLEDGEMENTS

This study was supported by a research grant from Klinge Pharma Munich/FRG. We gratefully acknowledge the skillfull technical assistance of our lab technicians Ursula Judenhofer, Christina Lemmermann, Sybille Kirzinger, and Iris Reithmeier. Without their ready acceptance to work overtime this study would have been impossible to perform.